Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Biological activity of Ab is a critical component
- B cell-directed immunotherapies
- Antigen expression during B cell development
- B lymphocyte targets for immunotherapy
- CD20 immunotherapy for lymphoma
- CD20-directed immunotherapies (1)
- CD20-directed immunotherapies (2)
- CD20 immunotherapy for lymphoma - rituximab
- Key Ab properties for Ab-mediated immunotherapy
- Antibody structure and classes
- Affinity and avidity
- Immunogenicity (1)
- Immunogenicity (2)
- Half-life
- Ab effects on B cell function
- CD20: function, structure and expression
- CD20 hypothetical structure on B lymphocytes
- CD20 complex-mediated Ca2+ conductance
- Ab binding to CD20 inhibits decrease in [Ca2+]i
- CD20-deficient B cell [Ca2+]i responses
- Membrane spanning-4A gene family
- MS4a expression by mouse tissues
- Antibody effects on B cell function
- Antibody dependant cellular cytotoxicity
- Mouse anti-mouse CD20 monoclonal antibodies
- MB20 mAb depletion of B cells in vivo
- CD20 mAb effects on bone marrow B cells
- CD20 mAb depletes blood B cells
- CD20 mAb depletes spleen B cells in vivo
- CD20 mAb eliminates majority of mature B cells
- B cell depletion after CD20 mAb treatment
- The peritoneal cavity provides a protective niche
- Inflammation abrogates the protective niche
- FcR expression is required for B cell depletion
- B cell depletion by CD20 requires monocytes
- CD20 antibodies induce ADCC
- Complement dependent cytotoxicity (CDC)
- B cell depletion does not require C'/ T/ NK cells
- Mouse survival following A20 lymphoma inoculation
- CD20 treatment eliminates most of mature B cells
- Non-responsiveness and resistance to CD20 mAb
- CD20 immunotherapy for autoimmunity
- S.c CD20 mAb administration is effective
- B cell depletion in TSK/+ mice by CD20 mAb
- B cell depletion reduces skin fibrosis
- CD20-directed immuotherapies
- Mechanistic studies of CD20 mAb immunotherapy
Topics Covered
- Antibody targeting of B-cell malignancies and autoimmunity
- CD20 antibody immunotherapy
- CD20 structure and function
- Antibody-dependent cellular cytotoxicity
- Complement-dependent cytotoxicity
- Mouse models of CD20 immunotherapy
- Lymphoma immunotherapy
- Immunotherapy for autoimmunity
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tedder, T. (2007, October 1). CD20 antibodies in the targeting of B-cell malignancies and autoimmunity [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/GIRG6026.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Thomas Tedder has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
CD20 antibodies in the targeting of B-cell malignancies and autoimmunity
A selection of talks on Cancer
Hide